PE20001499A1 - Composiciones farmaceuticas de n-benzoil-estaurosporina - Google Patents

Composiciones farmaceuticas de n-benzoil-estaurosporina

Info

Publication number
PE20001499A1
PE20001499A1 PE2000000113A PE0001132000A PE20001499A1 PE 20001499 A1 PE20001499 A1 PE 20001499A1 PE 2000000113 A PE2000000113 A PE 2000000113A PE 0001132000 A PE0001132000 A PE 0001132000A PE 20001499 A1 PE20001499 A1 PE 20001499A1
Authority
PE
Peru
Prior art keywords
staurosporin
glyceride
oil
benzoil
cotensoactive
Prior art date
Application number
PE2000000113A
Other languages
English (en)
Spanish (es)
Inventor
Graham Paul Matthews
Barbara Haberlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001499(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001499A1 publication Critical patent/PE20001499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2000000113A 1999-02-16 2000-02-14 Composiciones farmaceuticas de n-benzoil-estaurosporina PE20001499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds

Publications (1)

Publication Number Publication Date
PE20001499A1 true PE20001499A1 (es) 2001-01-12

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000113A PE20001499A1 (es) 1999-02-16 2000-02-14 Composiciones farmaceuticas de n-benzoil-estaurosporina

Country Status (34)

Country Link
US (3) US20020061873A1 (cg-RX-API-DMAC10.html)
EP (1) EP1152750B1 (cg-RX-API-DMAC10.html)
JP (2) JP5057610B2 (cg-RX-API-DMAC10.html)
KR (2) KR100880859B1 (cg-RX-API-DMAC10.html)
CN (1) CN100367930C (cg-RX-API-DMAC10.html)
AR (2) AR022589A1 (cg-RX-API-DMAC10.html)
AT (1) ATE430554T1 (cg-RX-API-DMAC10.html)
AU (1) AU765776B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0008228B8 (cg-RX-API-DMAC10.html)
CA (1) CA2362277C (cg-RX-API-DMAC10.html)
CL (1) CL2009001682A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ303979B6 (cg-RX-API-DMAC10.html)
DE (1) DE60042151D1 (cg-RX-API-DMAC10.html)
DK (1) DK1152750T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP083351A (cg-RX-API-DMAC10.html)
ES (1) ES2326783T3 (cg-RX-API-DMAC10.html)
GB (1) GB9903547D0 (cg-RX-API-DMAC10.html)
HK (1) HK1045807B (cg-RX-API-DMAC10.html)
HU (1) HUP0105364A3 (cg-RX-API-DMAC10.html)
ID (1) ID30504A (cg-RX-API-DMAC10.html)
IL (3) IL144512A0 (cg-RX-API-DMAC10.html)
MY (1) MY128362A (cg-RX-API-DMAC10.html)
NO (1) NO331232B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ513529A (cg-RX-API-DMAC10.html)
PE (1) PE20001499A1 (cg-RX-API-DMAC10.html)
PL (1) PL198330B1 (cg-RX-API-DMAC10.html)
PT (1) PT1152750E (cg-RX-API-DMAC10.html)
RU (1) RU2266121C2 (cg-RX-API-DMAC10.html)
SI (1) SI1152750T1 (cg-RX-API-DMAC10.html)
SK (1) SK286967B6 (cg-RX-API-DMAC10.html)
TR (1) TR200102385T2 (cg-RX-API-DMAC10.html)
TW (1) TWI240636B (cg-RX-API-DMAC10.html)
WO (1) WO2000048571A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200106677B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2002076432A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CN101897662B (zh) * 2002-07-23 2013-05-22 诺瓦提斯公司 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
RU2560677C2 (ru) * 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2013042069A1 (en) 2011-09-22 2013-03-28 Ariel-University Research And Development Company, Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (cg-RX-API-DMAC10.html) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DK0589843T3 (da) * 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
PT988046E (pt) * 1997-01-30 2004-12-31 Novartis Ag Composicoes farmaceuticas sem oleo contendo ciclosporina a
SI0999826T1 (en) 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
DK0999838T3 (da) 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
PL198330B1 (pl) 2008-06-30
AR022589A1 (es) 2002-09-04
WO2000048571A1 (en) 2000-08-24
HUP0105364A2 (hu) 2002-05-29
JP2002537242A (ja) 2002-11-05
NZ513529A (en) 2003-10-31
GB9903547D0 (en) 1999-04-07
CN100367930C (zh) 2008-02-13
US20140056974A1 (en) 2014-02-27
ATE430554T1 (de) 2009-05-15
US8722664B2 (en) 2014-05-13
IL144512A0 (en) 2002-05-23
US8575147B2 (en) 2013-11-05
SI1152750T1 (sl) 2009-10-31
DK1152750T3 (da) 2009-08-24
NO20013964D0 (no) 2001-08-15
JP5057610B2 (ja) 2012-10-24
CZ303979B6 (cs) 2013-07-31
BRPI0008228B8 (pt) 2021-05-25
NO20013964L (no) 2001-10-15
BR0008228A (pt) 2001-10-30
AR082579A2 (es) 2012-12-19
KR100880859B1 (ko) 2009-01-30
HK1045807B (zh) 2008-12-05
CA2362277A1 (en) 2000-08-24
HK1045807A1 (zh) 2002-12-13
KR20080064914A (ko) 2008-07-09
CA2362277C (en) 2010-03-30
KR20010093281A (ko) 2001-10-27
RU2266121C2 (ru) 2005-12-20
ECSP083351A (es) 2008-08-29
PT1152750E (pt) 2009-08-07
BRPI0008228B1 (pt) 2016-08-23
EP1152750A1 (en) 2001-11-14
AU3154200A (en) 2000-09-04
DE60042151D1 (de) 2009-06-18
PL350556A1 (en) 2002-12-16
US20020061873A1 (en) 2002-05-23
IL192666A0 (en) 2009-02-11
MY128362A (en) 2007-01-31
JP2012111763A (ja) 2012-06-14
SK286967B6 (sk) 2009-08-06
HUP0105364A3 (en) 2003-02-28
CN1339963A (zh) 2002-03-13
IL144512A (en) 2011-03-31
CZ20012931A3 (cs) 2001-11-14
EP1152750B1 (en) 2009-05-06
SK11722001A3 (sk) 2001-12-03
US20080070897A1 (en) 2008-03-20
ES2326783T3 (es) 2009-10-20
AU765776B2 (en) 2003-10-02
CL2009001682A1 (es) 2010-07-23
TWI240636B (en) 2005-10-01
ZA200106677B (en) 2003-01-14
ID30504A (id) 2001-12-13
TR200102385T2 (tr) 2002-09-23
NO331232B1 (no) 2011-11-07

Similar Documents

Publication Publication Date Title
CA2362277A1 (en) Spontaneously dispersible n-benzoyl staurosporine compositions
DE4345199C2 (de) Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
NZ512287A (en) Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
CA2190485A1 (en) Lacrimal gland specific emulsions for topical application to ocular tissue
WO2002039983A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AP2000001943A0 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
JP2008537960A5 (cg-RX-API-DMAC10.html)
MX373796B (es) Composición de solubilización farmacéuticamente aceptable y forma de dosificación farmacéutica que contiene la misma.
AR043106A2 (es) Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica
CA2284000A1 (en) Hydrophilic binary systems for the administration of cyclosporine
US20150165050A1 (en) Cyclosporin compositions
RU2012120388A (ru) Фармацевтические композиции, включающие производное камптотецина
EP0939631A1 (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
JP2005539003A (ja) 経口投与用シクロスポリン含有医薬組成物
KR970704433A (ko) 의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition)
JP2006501208A (ja) 経口投与用シクロスポリン、プロピレングリコールエステルおよび非イオン性界面活性剤含有医薬組成物。
JP2017503866A (ja) デュタステリドを含む自己乳化型薬物送達システムのための組成物
KR970706803A (ko) 경구용 시클로스포린 제형(oral cyclosporin formulations)
JP2005539002A (ja) シクロスポリン含有経口医薬組成物
JPS62135409A (ja) 養毛化粧料
KR101612257B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
JP7733993B2 (ja) 外用組成物
JP7733992B2 (ja) 外用組成物
JP7733991B2 (ja) 外用組成物
US20040110667A1 (en) Carrier system for cyclosporin pharmaceutical compositions

Legal Events

Date Code Title Description
FC Refusal